Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2008-04-17 | Dr. Rhodes is chair of the Compensation and Stock Option Committee of the Board of Directors. Total compensation for 2007 was $6,000. |
| 2009-04-17 | Dr. Rhodes is chair of the Compensation and Stock Option Committee and a member of the Nominating Committee of the Board of Directors. She is a founding partner of AlcheraBio, LLC of Metuchen, New Jersey, an animal health consulting and contract research firm, which firm was acquired in October 2008 by Argenta, a New Zealand animal health formulations and contract manufacturing organization. She is an adjunct professor for the Graduate School of Animal Science at Rutgers University and a member of the Board of Directors of the Alliance for Contraception for Cats and Dogs (a non-profit organization). From 1998 to 2001, she was a Director of Development Projects and New Technology Assessment at Merial Ltd, a joint venture between Merck and Sanofi-Aventis. Prior to that, she held various research positions at Merck Research Laboratories and Sterling Drug Company. She held several teaching positions and worked as a bovine veterinarian in private practice. She earned her Ph.D. in Physiology/Immunology from Cornell University and her V.M.D. from the Pennsylvania School of Veterinary Medicine. Director compensation for 2008 was $7,000. |
| 2012-04-25 | Dr. Rhodes is chair of the Compensation and Stock Option Committee and a member of the Audit Committee of the Board of Directors. |
| 2013-04-18 | LINDA RHODES, V.M.D., Ph.D: Age: 63 Director since: August 2005 Dr. Rhodes is chair of the Compensation and Stock Option Committee and a member of the Audit Committee of the Board of Directors. She is the Chief Scientific Officer (CSO) of Aratana Therapeutics. The Audit Committee's members are Dr. Maxwell, Dr. Rhodes and Mr. Rothschild. The Compensation Committee's members are Dr. Maxwell, Dr. Rhodes and Mr. Rothschild. |
| 2014-04-24 | Dr. Rhodes is chair of the Compensation and Stock Option Committee and a member of the Audit Committee of the Board of Directors. |
Data sourced from SEC filings. Last updated: 2025-12-06